BeiGene, Ltd. (ONC)vsOramed Pharmaceuticals Inc (ORMP)
ONC
BeiGene, Ltd.
$283.45
+2.81%
HEALTHCARE · Cap: $31.62B
ORMP
Oramed Pharmaceuticals Inc
$3.50
+2.34%
HEALTHCARE · Cap: $141.46M
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 267052% more annual revenue ($5.34B vs $2.00M). ORMP leads profitability with a 21.9% profit margin vs 5.4%. ORMP trades at a lower P/E of 3.5x. ORMP earns a higher WallStSmart Score of 49/100 (D+).
ONC
Hold42
out of 100
Grade: D
ORMP
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1983.5%
Fair Value
$16.86
Current Price
$283.45
$266.59 premium
Margin of Safety
+93.1%
Fair Value
$46.80
Current Price
$3.50
$43.30 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 32.8% year-over-year
Conservative balance sheet, low leverage
Attractively priced relative to earnings
Reasonable price relative to book value
Every $100 of equity generates 25 in profit
Keeps 22 of every $100 in revenue as profit
Earnings expanding 40.9% YoY
Areas to Watch
0.0% earnings growth
ROE of 7.5% — below average capital efficiency
5.4% margin — thin
Premium valuation, high expectations priced in
Smaller company, higher risk/reward
Revenue declined 100.0%
Negative free cash flow — burning cash
Operating margin of -6.5%
Comparative Analysis Report
WallStSmart ResearchBull Case : ONC
The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.
Bull Case : ORMP
The strongest argument for ORMP centers on P/E Ratio, Price/Book, Return on Equity. Profitability is solid with margins at 21.9% and operating margin at -6.5%.
Bear Case : ONC
The primary concerns for ONC are EPS Growth, Return on Equity, Profit Margin. A P/E of 111.0x leaves little room for execution misses.
Bear Case : ORMP
The primary concerns for ORMP are Market Cap, Revenue Growth, Free Cash Flow.
Key Dynamics to Monitor
ONC profiles as a hypergrowth stock while ORMP is a declining play — different risk/reward profiles.
ORMP carries more volatility with a beta of 1.28 — expect wider price swings.
ONC is growing revenue faster at 32.8% — sustainability is the question.
ONC generates stronger free cash flow (131M), providing more financial flexibility.
Bottom Line
ORMP scores higher overall (49/100 vs 42/100), backed by strong 21.9% margins. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Oramed Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Oramed Pharmaceuticals Inc. is dedicated to the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for the administration of polypeptides. The company is headquartered in New York, New York.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?